This is a working overview of thymosin beta-4, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-08 and is reviewed periodically as new material appears.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized cake or fluffy solid |
| Water solubility | High | Dissolves in water and neutral buffers |
| Dry storage | -20 °C or below | Dry, dark, desiccated |
| Reconstituted storage | Frozen, single thaw | Repeated freeze-thaw promotes loss |
| Purity method | Reverse-phase HPLC | Peak area read at 214 or 220 nm |
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Avobenzone (trade names Parsol 1789, Milestab 1789, Eusolex 9020, Escalol 517, Neo Heliopan 357 and others, INCI Butyl Methoxydibenzoylmethane) is an organic molecule and an oil-soluble ingredient used in sunscreen products to absorb the full spectrum of UVA rays.
== Mechanism of action == After binding to lipopolysaccharide (LPS) in the outer membrane of Gram-negative bacteria, polymyxins disrupt both the outer and inner membranes. The hydrophobic tail is important in causing membrane damage, suggesting a detergent-like mode of action. Removal of the hydrophobic tail of polymyxin B yields polymyxin nonapeptide, which still binds to LPS, but no longer kills the bacterial cell. However, it still detectably increases the permeability of the bacterial cell wall to other antibiotics, indicating that it still causes some degree of membrane disorganization. Gram-negative bacteria can develop resistance to polymyxins through various modifications of the LPS structure that inhibit the binding of polymyxins to LPS. Antibiotic resistance to this drug has been increasing, especially in southern China. Recently the gene mcr-1, which confers the antibiotic resistance, has been isolated from bacterial plasmids in Enterobacteriaceae.
== Pharmacokinetics == Agmatine is present in small amounts in plant-, animal-, and fish-derived foodstuff, and gut microbial production is an added source for agmatine. Oral agmatine is absorbed from the gastrointestinal tract and readily distributed throughout the body. Rapid elimination from non-brain organs of ingested (un-metabolized) agmatine by the kidneys has indicated a blood half life of about 2 hours.
== Interactions == The combination of piperacillin and tazobactam, commonly branded as Zosyn, improves their overall bactericidal activity as amino-benzylpenicillins and ureidopencillins work synergistically with β-lactamase inhibitors. Concurrent use or unregulated dosages of piperacillin results in increasing levels of piperacillin within the body, prolonging neuromuscular transmission blockages created by non-depolarizing muscle relaxants, and disruptions in urine tests for glucose. Some compounds that may interfere with the bactericidal activity of piperacillin include chloramphenicol, macrolides, and sulfonamides. Following two studies conducted in 1986 and 2006, piperacillin was found to inhibit the removal of methotrexate in animal kidneys. Furthermore, in the presence of piperacillin-tazobactam, the decay time for methotrexate triples in comparison to the normal half-life, leaving the patient exposed to cytotoxic effects produced by the chemical agent. While penicillin antibiotics generally work synergistically with aminoglycosides by enhancing their penetration of bacterial membranes, they can also work adversely by inactivating them. A reformulation of ethylenediaminetetraacetic acid and piperacillin-tazobactam has produced results showing an increase in their affinity with amikacin and gentamicin in vitro, enabling the process of simultaneous Y-site infusion to occur. However, tobramycin was found to be incompatible as a combination through Y-site infusion.
==== Switzerland ==== In Switzerland cider is called Suure Most or Saft in the German-speaking part, Cidre in the Romandy, and sidro in the Italian-speaking regions. The drink was made popular in the 19th century when apple production increased due to progress in pomology. At the turn of the century, cider consumption was at 28.1 litres per person. In the 1920s, advantages in the pasteurisation of apple juice and the emerging temperance movement led to a strong decrease of cider production. Today, typical Swiss cider consists of fermented apple juice mixed with 30% fresh juice which is added for sweetness. This drink is then pasteurised and force-carbonated. Imported cider is not common as according to Swiss laws cider must contain more than 70% of juice.
Sources: en.wikipedia.org
=== Experience of treatment === Patients involved in treatment sometimes felt that treatment focused on biological aspects of body weight and eating behaviour change rather than their perceptions or emotional state. Patients felt that a therapist's trust in them shown by being treated as a complete person with their own capacities was significant. Some patients defined recovery from AN in terms of reclaiming a lost identity. Additionally, access to timely treatment can be hindered by systemic challenges within the medical system. Some individuals have reported experiencing delays in treatment, particularly when transitioning from adolescence to adulthood. Healthcare workers involved in the treatment of anorexia reported frustration and anger to setbacks in treatment and noncompliance and were afraid of patients dying. Some healthcare workers felt that they did not understand the treatment and that medical doctors were making decisions. They may feel powerless to improve a patient's situation and deskilled as a result. Healthcare workers involved in monitoring patients consumption of food felt watched themselves. Healthcare workers often feel a degree of moral dissonance of not being in control of outcomes which they may protect against by focusing on individual tasks, avoiding identifying with patients (for example by making their eating behavior very different and not sharing personal information with patients), and blaming patients for their distress. Healthcare workers would inflexibly follow process to avoid responsibility.
Larson received media attention for scolding members of Congress for shutting down the government on September 30, 2013. Larson was among the 46 Democrats who voted against final passage of the Fiscal Responsibility Act of 2023 in the House.
== Distribution and habitat == Coffee senna is native to the southern United States of America, Mexico and South America, but is an aggressive, pantropical weed. In Australia it is widespread but scattered in the north of Western Australia, the Northern Territory, South Australia, Queensland and New South Wales.
TAAR1 also couples G-protein alpha subunit G13; when triggered by amphetamine, this pathway activates Ras homolog A (RhoA) and its downstream protein kinase, Rho-associated coiled-coil kinase (ROCK), an effect that internalizes both DAT and the neuronal glutamate transporter EAAT3. Transporter internalization via TAAR1's G13-coupled pathway is transient because Gs-cAMP-PKA signaling functionally inhibits RhoA's downstream activity; once intracellular cAMP sufficiently accumulates, PKA is activated and phosphorylates RhoA, thereby terminating ROCK-mediated transporter internalization. In addition to presynaptic actions that regulate DAT, TAAR1 activation exerts a somatodendritic inhibitory influence on midbrain dopamine neurons by reducing their firing rate via G protein-coupled inwardly-rectifying potassium channels, an effect that is expected to reduce action potential-dependent (vesicular) dopamine release into the synaptic cleft. Amphetamine's effect on intracellular calcium is associated with DAT phosphorylation through Ca2+/calmodulin-dependent protein kinase II alpha (CAMKIIα), in turn producing dopamine efflux. Because conventional PKC isoforms can be activated by Ca2+ and diacylglycerol, elevated intracellular calcium can promote PKC-dependent DAT phosphorylation independent of TAAR1.
=== Other awards === Fenn received his Nobel Prize fairly late in his career. Prior to being honored by the Nobel Foundation, Fenn had received numerous other awards. Early in his career, Fenn's research was focused on molecular beams, leading him to be named an honorary president of the Sixth International Symposium on Molecular Beams in 1977, and the first fellow of the International Molecular Beam Symposium in 1985. In 1982, the Alexander von Humboldt Foundation presented him with their U.S. Senior Scientist Award. Fenn's work in mass spectrometry earned him another spate of awards later in his career. In 1992, the American Society for Mass Spectrometry presented him with their Award for Distinguished Contributions in Mass Spectrometry. The International Society of Mass Spectrometry honored him with the Thomson Medal in 2000, and in the same year the American Chemical Society presented him with the Award for Advancements in Chemical Instrumentation. He was awarded the Association of Biomolecular Resource Facilities Award for outstanding contributions to Biomolecular Technologies in 2002. In 2003, Fenn was honored by his alma mater with the Wilbur Cross Medal, the Yale Graduate School Alumni Association's highest honor. Fenn maintained numerous professional affiliations, including membership in the American Chemical Society, the American Society for Mass Spectrometry, Sigma Chi, the American Association of University Professors and the Alexander von Humboldt Association of America.
Sources: en.wikipedia.org
== Pharmacology == Pegcetacoplan acts as a complement inhibitor, specifically targeting complement protein C3, which plays a crucial role in the pathogenesis of paroxysmal nocturnal hemoglobinuria. In individuals with paroxysmal nocturnal hemoglobinuria, there is a heightened and uninhibited complement activity, which may lead to intravascular (inside blood vessels) or extravascular (within the liver or spleen) hemolysis. By binding to and inhibiting C3, pegcetacoplan helps regulate complement activation, thereby reducing red blood cell destruction, anemia, blood clot formation, and improving bone marrow function. This targeted mechanism of action makes pegcetacoplan the first-in-class medication for the treatment of paroxysmal nocturnal hemoglobinuria, offering a promising therapeutic approach to address the underlying complement dysregulation in this condition.
== Current research == In her Yale laboratory, Horsley has studied the cellular and molecular pathways involved in skin tissue development and maintenance, as well as the relationship between fat cells in the skin, wound healing, regeneration of hair follicles, and the formation of keratinocytes during embryonic development. Horsley currently studies adult stem cells in epithelial skin tissue and how these cells contribute to wound healing and the development of cancer, using the mouse as a genetic model system. Horsley revolutionized the field of epithelial stem cell biology by identifying skin adipocyte stem cells, establishing a major role for these progenitor cells in regulating turnover, rejuvenation and wound repair of the skin epidermis and hair follicles. She found that within epithelial tissues, cells tend to confine to distinct micro-environments. Mechanisms of adipocyte cells in tissue homeostasis and regeneration are not well understood. Horsley discovered the source of both fat cells and immune cells as local signals, as the hormone signal, prolactin, is responsible for stem cell activity and the regeneration of skin cells. Together, her laboratory also found that cell differentiation of adipocytes and hair growth occur simultaneously, and when the cell differentiation process (adipogenesis) ceases, hair growth stops and the follicles deteriorate. Her team identified specific adipose progenitors in the skin, which indicated the necessity of these cells to sufficiently induce hair follicle growth.
== Properties == PEEK is a semicrystalline thermoplastic with excellent mechanical and chemical resistance properties that are retained to high temperatures. The processing conditions used to mould PEEK can influence the crystallinity and hence the mechanical properties. Its Young's modulus is 3.6 GPa and its tensile strength is 90 to 100 MPa. PEEK has a glass transition temperature of around 143 °C (289 °F) and melts around 343 °C (662 °F). Some grades have a useful operating temperature of up to 250 °C (482 °F). The thermal conductivity increases nearly linearly with temperature between room temperature and solidus temperature. It is highly resistant to thermal degradation, as well as to attack by both organic and aqueous environments. It is attacked by halogens and strong Brønsted and Lewis acids, as well as some halogenated compounds and aliphatic hydrocarbons at high temperatures. It is soluble in concentrated sulfuric acid at room temperature, although dissolution can take a very long time unless the polymer is in a form with a high surface-area-to-volume ratio, such as a fine powder or thin film. It has high resistance to biodegradation.
== SAR and the SAR paradox == The basic assumption for all molecule-based hypotheses is that similar molecules have similar activities. This principle is also called Structure–Activity Relationship (SAR). The underlying problem is therefore how to define a small difference on a molecular level, since each kind of activity, e.g. reaction ability, biotransformation ability, solubility, target activity, and so on, might depend on another difference. Examples were given in the bioisosterism reviews by Patanie/LaVoie and Brown. In general, one is more interested in finding strong trends. Created hypotheses usually rely on a finite number of chemicals, so care must be taken to avoid overfitting: the generation of hypotheses that fit training data very closely but perform poorly when applied to new data. The SAR paradox refers to the fact that it is not the case that all similar molecules have similar activities.
Sources: en.wikipedia.org
Short transit at ambient temperature is generally tolerated, but long-term storage at room temperature is not recommended. Heat, moisture, and light all accelerate degradation. Cold, dry, dark storage is the conventional choice.
Suppliers typically quote a percentage derived from reverse-phase HPLC peak area. That figure reflects the relative amount of the main peak and does not by itself confirm identity or exclude related impurities. Mass spectrometry is commonly paired with it for confirmation.
Peptides purified by reverse-phase chromatography often carry trifluoroacetate as a counter-ion, which adds mass and can affect solubility and apparent behavior in assays. Acetate and hydrochloride forms are also offered. Knowing which form is present matters when calculating how much peptide a given weight contains.
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.